F

Faes Farma SA
MAD:FAE

Watchlist Manager
Faes Farma SA
MAD:FAE
Watchlist
Price: 4.73 EUR 0.21% Market Closed
Market Cap: 1.5B EUR

Profitability Summary

Faes Farma SA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Faes Farma SA

Revenue
568.1m EUR
Cost of Revenue
-198m EUR
Gross Profit
370.1m EUR
Operating Expenses
-268.2m EUR
Operating Income
101.9m EUR
Other Expenses
3.2m EUR
Net Income
105.1m EUR

Margins Comparison
Faes Farma SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
ES
Faes Farma SA
MAD:FAE
1.5B EUR
65%
18%
19%
US
Eli Lilly and Co
NYSE:LLY
929B USD
83%
44%
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
481.1B USD
68%
27%
27%
CH
Roche Holding AG
SIX:ROG
251.1B CHF
74%
34%
15%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
82%
24%
16%
CH
Novartis AG
SIX:NOVN
205B CHF
76%
33%
26%
US
Merck & Co Inc
NYSE:MRK
241B USD
79%
38%
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
82%
42%
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
144B USD
75%
29%
16%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Faes Farma SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
ES
Faes Farma SA
MAD:FAE
1.5B EUR
15%
11%
13%
14%
US
Eli Lilly and Co
NYSE:LLY
929B USD
97%
19%
42%
25%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
481.1B USD
33%
13%
18%
13%
CH
Roche Holding AG
SIX:ROG
251.1B CHF
33%
10%
31%
19%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
22%
9%
18%
15%
CH
Novartis AG
SIX:NOVN
205B CHF
33%
14%
25%
18%
US
Merck & Co Inc
NYSE:MRK
241B USD
40%
15%
26%
21%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
71%
23%
57%
28%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
144B USD
11%
5%
11%
10%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less